India caps margins on 137 anticancer formulations

India’s National Pharmaceutical Pricing Authority has capped trade margins at 30% for 137 identified anticancer formulations, with revised prices scheduled to take effect on November 9, 2026. The measure applies to nonscheduled medicines, which are not covered by the government’s regular price controls, and is intended to limit markups in the supply chain. The cap was set in a Gazette notification issued October 17. Manufacturers must submit revised price details to the NPPA and State Drug Controllers within seven days of publication, even if a medicine’s price does not change. Retailers, distributors, hospitals and medical institutions must display updated price lists and apply the revised prices from the effective date. The NPPA expects maximum retail prices to fall by as much as 70% for some covered medicines. That is an estimate, not a uniform discount: the reduction will depend on each formulation’s existing price structure. Products already priced below the newly calculated ceiling must retain their lower price. The supplied reports do not establish the final revised price of each medicine or the savings patients will realize. The list includes medicines such as...